{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-148602","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.753242+00:00","generated_at":"2026-06-01T07:37:17.357473+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"bluebird bio CFO Christopher Krawtschuk departs June 10; O. James Sterling appointed as CFO","bullets":["CFO Christopher Krawtschuk to depart June 10, 2024, not due to any disagreement with the company on accounting policies or strategy.","O. James Sterling, formerly CFO of Renalytix plc, appointed as CFO and principal accounting officer effective June 10, 2024.","Sterling's compensation: $500k base salary, $100k sign-on bonus, 45% target bonus, and initial equity grant of 300k options, 100k RSUs, and 50k PRSUs (subject to shareholder approval).","Severance upon termination without cause or for good reason includes one times base salary (or one times base plus target bonus within 12 months of Change in Control) plus COBRA subsidy for 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-148602","json":"https://secwatch.observer/filing/0001193125-24-148602.json","markdown":"https://secwatch.observer/filing/0001193125-24-148602.md","text":"https://secwatch.observer/filing/0001193125-24-148602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/d796778d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:37:17.357473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b9d61999b","claim":"Christopher Krawtschuk departed as Chief Financial Officer at bluebird bio, Inc..","evidence_excerpt":"Effective June 10, 2024 (the “Separation Date”), Christopher Krawtschuk will depart bluebird bio, Inc. (the “Company”) and cease serving as Chief Financial Officer and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will depart"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"7a720efbab","claim":"O. James Sterling was appointed as Chief Financial Officer at bluebird bio, Inc..","evidence_excerpt":"On May 28, 2024, the Board of Directors (the “Board”) appointed O. James Sterling as Chief Financial Officer of the Company and designated Mr. Sterling as principal accounting officer, effective as of the date Mr. Sterling commences employment with the Company, which is expected to be June 10, 2024 (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}